What is Gendius?
Gendius specializes in health data and digital solutions designed to improve patient outcomes, particularly for those managing metabolic diseases such as diabetes. Their core offering, Intellin, is a sophisticated web-based platform that delivers personalized education and management tools to individuals with diabetes. Concurrently, Intellin provides healthcare professionals and insurers with valuable insights into patient interventions, facilitating more effective care delivery. The company's approach is deeply rooted in collaboration with patients and healthcare providers to ensure their solutions address genuine needs, with efficacy validated through their extensive pharmaceutical industry experience. Gendius's strategic focus is on empowering individuals with diabetes and supporting healthcare providers in optimizing diabetes management and care.
How much funding has Gendius raised?
Gendius has raised a total of $300K across 1 funding round:
Other Financing Round
$300K
Other Financing Round (2020): $300K, investors not publicly disclosed
What's next for Gendius?
With the recent influx of $300K in strategic investment, Gendius is poised for accelerated growth and market expansion. This substantial backing, contributing to its $300K in overall financing, suggests a late-stage development phase, likely enabling the company to enhance its Intellin platform, broaden its reach to more patients and healthcare systems, and potentially explore new therapeutic areas within metabolic health. The company's emphasis on data-driven insights and validated efficacy positions it to further solidify its role in transforming diabetes care through digital innovation.
See full Gendius company page
